Texas institute is improving the quality of healthcare in one of America’s most disadvantaged communities

Plus a haul of label extensions for Sanofi, while Novartis and Roche withdraw applications

Chris Viehbacher could reprioritize Biogen via BD, while David Epstein could get Seagen’s launches on track

Safety results and efficacy signals from Phase II readouts send Bayer’s asundexian and BMS’s milvexian

DISEASE CATEGORY: Cardiovascular
INDICATION: Ischemia/reperfusion injury Nanoparticles loaded with a peptide inhibitor of GNA13, a G protein subunit, could treat cardiac ischemia/reperfusion injury.

Hudson’s new growth strategy for Sanofi hinges on expanding Dupixent and growing cancer, rare